Gisela Kobelt (Former)
21 – 28 of 28
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- next »
- 2008
-
Mark
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
(
- Contribution to journal › Article
-
Mark
The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
(
- Contribution to journal › Article
-
Mark
Disease status, costs and quality of life of patients with rheumatoid arthritis in France: The ECO-PR Study.
(
- Contribution to journal › Article
- 2007
-
Mark
Costs of rheumatoid arthritis in Hungary
(
- Contribution to journal › Letter
-
Mark
Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials
(
- Contribution to journal › Article
- 2006
-
Mark
Health economic issues in rheumatoid arthritis
(
- Contribution to journal › Scientific review
-
Mark
Costs and quality of life of patients with multiple sclerosis in Europe
(
- Contribution to journal › Article
- 1998
-
Mark
Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany
(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- next »